Haluzík M, Cheng A, Müller‐Wieland D, et al. - This study was undertaken to determine if clinical outcomes with insulin glargine 300 U/mL (Gla‐300) and insulin degludec 100 U/mL (IDeg‐100) were affected by renal function in a pre‐specified subgroup analysis from the BRIGHT trial. For this analysis, candidates were randomised 1:1 to evening Gla‐300 (n = 466) or IDeg‐100 (n = 463) and stratified based on baseline estimated glomerular filtration rate (eGFR). According to findings, kidney function appears to have an impact on the glucose‐lowering effects of Gla‐300 vs IDeg‐100 in insulin‐naïve T2D. In patients with eGFR < 60 mL/min/1.73 m², greater HbA_1c reductions with Gla‐300 without increase in hypoglycaemia risk have been observed.